Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2010

View Archived Issues

Bruton's tyrosine kinase inhibitors reported by CGI and Genentech

Multikinase inhibitor regorafenib evaluated in NSCLC; interim phase I data presented

Maximum tolerated dose of acadesine identified in chronic lymphocytic leukemia patients

Genetic variations linked to pancreatic cancer risk

Brivaracetam dose adjustment not needed for renal dysfunction

SBR-759 superior to sevelamer HCI for hyperphosphatemia in Asian hemodialysis patients

Transition Therapeutics begins phase I study of TT-301 for CNS indications

Pfizer claims cholecystokinin-1 agonists for obesity and co-morbidities

Novel PDE5A inhibitors claimed by Chinese scientists

Janssen claims rifamycin derivatives as antibacterials

M3 receptor antagonists under study at Argenta and AstraZeneca

Myriad Pharmaceuticals changes name to Myrexis, will focus on oncology programs

Sepracor's Omnaris HFA meets primary endpoint in phase III study

Strativa receives FDA approval for Zuplenz oral soluble film

ADVENTRX reports encouraging 9-month data from stability tests of Exelbine

BioSante reports results from phase II study of its Pill-Plus oral contraceptive

FDA approves Purdue Pharma's Butrans transdermal system CIII for chronic pain

Corcept begins dosing in phase III study of Corlux in Cushing's syndrome

AstraZeneca and MRC Technology form alliance to share compound libraries

Circadin approved in the E.U. for 13-week treatment for primary insomnia

X-Chem and Roche collaborate on drug discovery

Alimera submits NDA to the FDA for Iluvien in diabetic macular edema

Cell Therapeutics files updated Pediatric Investigation Plan for pixantrone to the EMA

MorphoSys receives grant from German government for MOR-202 cancer program

Clemizole may yield high-level synergy with protease inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Sumitomo’s DSP-3456 exerts antidepressant-like effects
BioWorld Science
About one-third of patients with major depressive disorder (MDD) are treatment resistant. Ketamine is very effective in treatment-resistant depression, but it is...